Binghe Xu

41PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursArtificial life and complex adaptive systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Sep 27, 2026
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.

|Aug 07, 2026
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

|Mar 16, 2026
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Fei Ma, Min Yan, Wei Li

|Feb 06, 2026
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial.

Pin Zhang, Tao Sun, Ying Wang

|Jan 05, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study.

Xuenan Peng, Ruixia Song, Ying Fan

|Jan 05, 2026
Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients.

Zihang Zeng, Zongbi Yi, Jing Hu

Pageof 7

Frequent Collaborators

6 joint publications

Qiao Li

5 joint publications

Shusen Wang

5 joint publications

Fei Ma

3 joint publications

Min Yan